Gelonghui, May 10丨An Biping (688393.SH) said on the interactive platform that the company's main business includes cancer screening and accurate diagnosis, mainly for hospital pathology departments, and has not yet involved human stem cell-related technology.
安必平(688393.SH)：暂未涉及人体干细胞相关技术
Anbipine (688393.SH): No technology related to human stem cells yet
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.